GFDA BOARD OF DIRECTORS MEETING MINUTES

Thursday November 5, 2020 8:00 AM  via Zoom

Times are approximate and agenda items may be taken out of order. Any Director with a potential conflict of interest on the agenda should state the conflict at the start of the meeting.

Board Members Present: Mark Macek, Len Watkins, Dwight Holman, Dave Fink, Ron Nelson, Susan Wolff, Mark Cappis, Rebecca Engum, Steve King, Ted Lewis, Corey Palmer, Jed Henthorne, Sherrie Arrey, Eric Hinebauch, Brian Hoven, Andreas Geranious, Jennifer Fritz, Heather McCartney-Duty, Trista Besich, Dianne Meinhardt, Earl Salley, Glenn Bliss, Forrest Ehlinger, Kylie Carranza, Daniel Rearden

Staff Present: Brett Doney, Jolene Schalper, Nathan Reiff, Lillian Sunwall, Soren Chargois, Rich Gannon, Tyler Menzales, Jill Kohles, Jana Williams

Guests: Jane Weber, Joan Redeen, Anthony Houtz

8:00  1. Introductions & Welcome New Directors – Len Watkins 8:05
2. Consent Agenda – Len Watkins
   1) Accept excused absences: Joe Briggs, John Gilbert, Casey Schreiner, Shane Etzwiler, Peyton Johnson.
      ACTION TAKEN: Motion to approve excused absences of 10/1/20 Board meeting. Motion: Steve King, Second: Ron Nelson. Motion carries.
   2) Approve minutes of 10/1/20 Board meeting.
      ACTION TAKEN: Motion to approve minutes of the 9/3/20 Board meeting. Motion: Mark Macek, Second: Dave Fink. Motion carries.

8:10  3. Reports – Len Watkins
      Do any Directors have questions about reports that were emailed out?

      Presentation and discussion on FY 2020 audit.

8:15  5. Wayfinding Plan– Tony Houtz of Cushing Terrell Presentation and discussion on Great Falls Wayfinding Plan.

8:45  6. Investment – Mark Cappis, Ted Lewis and Teresa Schreiner
      Discuss status of investment in GFDA’s mission.

8:50  7. Lending – Rebecca Engum and Jill Kohles
      Review September Loan Portfolio report.

8:55  8. Financial – Mark Macek and Brett Doney
      Review September financial reports.

9:00  9. CEO Report – Brett Doney 9:05

      Updates from Board members on issues affecting GFDA’s mission and organization.

9:10 11. Public Comment – Len Watkins
      Opportunity for public comment.

Approved 12/3/2020